LDH elevation

Baicalin exerts potent anti-tumor effects in BCa by upregulating ALDH2, thereby suppressing PD-L1-mediated M2 macrophage polarization and remodeling the tumor immune microenvironment. This mechanism provides a novel therapeutic strategy for combating BCa progression.

Patients with different LDH levels exhibit distinct clinical characteristics, laboratory findings, and long-term prognosis. Elevated LDH levels (> 338 U/L) and the presence of RPILD are associated with poor prognosis.

We identified factors associated with the detection of bESR1mut mutations at baseline and during treatment that could help identify patients who may benefit from ESR1-targeted therapies.

The positive expression of SATB1 is closely associated with a lower ECOG score and a favorable prognosis in patients with DLBCL.

Immunohistochemical profiling and LDH monitoring are crucial for prognostic assessment and treatment planning. More clinical data are needed to optimize management strategies for this rare entity.

Targeting this axis with LDHA inhibitor (stiripentol) and EGFR inhibitor (gefitinib) synergistically reversed cisplatin resistance in vitro and in vivo. This study unveils the "hypoxia-H3K18la-RBM15-IGFBP3" axis as a central driver of cisplatin resistance and proposes dual metabolic-epigenetic inhibition as a therapeutic strategy for refractory BCa.

The patient was treated with intrathecal methotrexate, cytarabine, and hydrocortisone, and later transitioned to an Ommaya reservoir. This case underscores the diagnostic and therapeutic challenges of isolated CNS recurrence in AML, including limited intrathecal drug delivery to nerve roots, the lack of CSF molecular profiling, and the potential for clonal evolution. Given the poor prognosis and therapeutic resistance associated with such cases, our findings support the consideration of CSF surveillance and combined systemic-intrathecal therapy in high-risk patients, particularly those with monocytic subtypes, elevated LDH, or complex cytogenetics.

Elevated IL-6 (p = 0.0003) and IL-8 (p = 0.004) in TIGIT-positive samples suggest a proinflammatory microenvironment promoting neutrophil recruitment and NETosis. TIGIT expression in the bone marrow of MM patients is associated with more aggressive disease features and an inflammatory microenvironment enriched with NET-forming neutrophils. These findings support TIGIT as a potential biomarker of disease severity and a therapeutic target in MM.

The analysis identified residual disease at midterm evaluation (P = 0.024) and LDH elevation ≥ 2000 U/L (P = 0.014) as independent prognostic factors affecting survival. The CNCL-B-NHL-2017 protocol demonstrated significant efficacy in treating children with Burkitt leukemia.

This study suggests that CSF IL-6 and IL-10 are potential, widely available biomarkers for early detection of CNS involvement in NHL, offering a complement to traditional cytological analysis in clinical laboratories.

Panaxadiol suppresses cell proliferation, immunological evasion, and tumor formation in ESCC by inhibiting PD-L1 expression through the suppression of HIF-1α and STAT3.

LDHA inhibition emerges as a promising strategy to overcome ICI resistance in FH-deficient RCC and other glycolytic tumors. These findings underscore the therapeutic potential of targeting cancer metabolism to optimize immunotherapy efficacy.